武漢佰樂博代理：Recombinant Human 4-1BB/TNFRSF9/CD137 protein ,C- His Tag
產(chǎn)品鏈接：http://www.atagenix.com/product_detail-4882.html
產(chǎn)品購買聯(lián)系方式：027-65279366
純度：>90% as determined by SDS-PAGE
內(nèi)毒素：Please contact with the lab for this information.
蛋白構(gòu)建：A DNA sequence encoding the human TNFRSF9(Leu24-Gln186) was fused with the C-terminal His Tag
表達宿主：Mammalian cells
種屬：Homo sapiens (Human)
預(yù)測分子量：18.04kDa
制劑：Supplied as solution form in PBS or lyophilized from PBS .
運輸方式：In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
穩(wěn)定性&儲存：Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.
復(fù)溶：Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
分子別名：CD137, ILA
Note：For research use only .
參考文獻：
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function. PMID: 34580116
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. PMID: 35236742
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. PMID: 19384291
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. PMID: 34911975
Contributions of Costimulatory Molecule CD137 in Endothelial Cells. PMID: 34027676
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs. PMID: 30524423
CD137 (4-1BB) Engagement Fine-Tunes Synergistic IL-15- and IL-21-Driven NK Cell Proliferation. PMID: 31201235
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic. PMID: 34172583
The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity. PMID: 33362756
CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases. PMID: 32505443
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. PMID: 31013788
CD137: A checkpoint regulator involved in atherosclerosis. PMID: 29571029
CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. PMID: 27141396
The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention. PMID: 32052477
Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. PMID: 26773716
Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity. PMID: 34737267
Rationale for anti-CD137 cancer immunotherapy. PMID: 26751393
Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses? PMID: 26140043
CD137, implications in immunity and potential for therapy. PMID: 19273343
Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy. PMID: 37334375
The Roles of CD137 Signaling in Atherosclerosis. PMID: 27826331
CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. PMID: 20643812
Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients. PMID: 35275208
Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. PMID: 15181282
Targeting CD137 enhances the efficacy of cetuximab. PMID: 24837434
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. PMID: 25908780
CD137 Signal Mediates Cardiac Ischemia-Reperfusion Injury by Regulating the Necrosis of Cardiomyocytes. PMID: 35419772
The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus. PMID: 31500130
Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies. PMID: 26428392
Retracted: Activation of CD137 Signaling Enhances Vascular Calcification through c-Jun N-Terminal Kinase-Dependent Disruption of Autophagic Flux. PMID: 35431652
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. PMID: 36576322
Retraction of: Activation of CD137 Signaling Promotes Angiogenesis in Atherosclerosis via Modulating Endothelial Smad1/5-NFATc1 Pathway. PMID: 35414186
CD137 Signaling Regulates Acute Colitis via RALDH2-Expressing CD11b-CD103+ DCs. PMID: 32209473
4-1BB (CD137) in anticancer chimeras. PMID: 33147322
Soluble CD137 as a potential biomarker for severe COVID-19. PMID: 35810991
CD137 Ligand-CD137 Interaction is Required For Inflammasome-Associated Brain Injury Following Ischemic Stroke. PMID: 33073305
CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer. PMID: 35197968
Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer. PMID: 34980602
Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting. PMID: 33643694
[CD137 signaling promotes angiogenesis through regulating macrophage M1/M2 polarization]. PMID: 32842261
Identification of CD137- and CD137L-Expressing Cells in EL-4 Tumor. PMID: 33185879
Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage? PMID: 26970765
CD137-CD137L Signaling Affects Angiogenesis by Mediating Phenotypic Conversion of Macrophages. PMID: 31651672
CD137 signaling induces macrophage M2 polarization in atherosclerosis through STAT6/PPARδ pathway. PMID: 32247042
CD137 Signaling Is Critical in Fungal Clearance during Systemic Candida albicans Infection. PMID: 34068963
Immunotherapy with agonistic anti-CD137: two sides of a coin. PMID: 16212918
CD137 Costimulation Enhances the Antitumor Activity of Vγ9Vδ2-T Cells in IL-10-Mediated Immunosuppressive Tumor Microenvironment. PMID: 35784354
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. PMID: 24499671
CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma. PMID: 36089987
Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. PMID: 18599129
CD137 Signaling Promotes Endothelial Apoptosis by Inhibiting Nrf2 Pathway, and Upregulating NF-κB Pathway. PMID: 32587470
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. PMID: 24052693
Activating CD137 Signaling Promotes Sprouting Angiogenesis via Increased VEGFA Secretion and the VEGFR2/Akt/eNOS Pathway. PMID: 33162828
CD137 costimulation is associated with reduced herpetic stromal keratitis and with developing normal CD8+ T cells in trigeminal ganglia. PMID: 35766977
Biological activities of reverse signal transduction through CD137 ligand. PMID: 15618293
CD137-CRDI is not necessary in the role of contacting its natural ligand. PMID: 27430526
Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab. PMID: 26932429
CD137 Regulates Bone Loss via the p53 Wnt/β-Catenin Signaling Pathways in Aged Mice. PMID: 35846320
CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity. PMID: 34021248
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. PMID: 21074066
Anti-CD137 Cancer Immunotherapy Suppresses Tumor Growth-Letter. PMID: 29490949
Anti-CD137 Cancer Immunotherapy Suppresses Tumor Growth-Response. PMID: 29490950
CD137-CD137L Aggravates Calcification of Vascular Smooth Muscle Cell and Vasculature of ApoE-/- Mice Via Rab7-Mediated Autophagy. PMID: 35763154
CD137 costimulation enhances the antiviral activity of Vγ9Vδ2-T cells against influenza virus. PMID: 32488072
Role of ADAM10 and ADAM17 in Regulating CD137 Function. PMID: 33800462
CD137: A Member of the TNFR Family - in Psoriasis Skin Lesions in Comparison with Normal Skin Specimens. PMID: 33936220
